448 related articles for article (PubMed ID: 23986163)
1. Association between the type and length of tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis.
Wu JJ; Poon KY; Bebchuk JD
J Drugs Dermatol; 2013 Aug; 12(8):899-903. PubMed ID: 23986163
[TBL] [Abstract][Full Text] [Related]
2. Tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis, psoriatic arthritis, or both.
Wu JJ; Poon KY
J Drugs Dermatol; 2014 Aug; 13(8):932-4. PubMed ID: 25116971
[TBL] [Abstract][Full Text] [Related]
3. Do TNF inhibitors reduce the risk of myocardial infarction in psoriasis patients?
Armstrong AW
JAMA; 2013 May; 309(19):2043-4. PubMed ID: 23677316
[TBL] [Abstract][Full Text] [Related]
4. Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.
Esposito M; Gisondi P; Cassano N; Ferrucci G; Del Giglio M; Loconsole F; Giunta A; Vena GA; Chimenti S; Girolomoni G
Br J Dermatol; 2013 Sep; 169(3):666-72. PubMed ID: 23647206
[TBL] [Abstract][Full Text] [Related]
5. Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody.
Solau-Gervais E; Laxenaire N; Cortet B; Dubucquoi S; Duquesnoy B; Flipo RM
Rheumatology (Oxford); 2006 Sep; 45(9):1121-4. PubMed ID: 16510526
[TBL] [Abstract][Full Text] [Related]
6. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept.
Weinberg JM; Saini R
Cutis; 2003 Jan; 71(1):25-9. PubMed ID: 12553627
[TBL] [Abstract][Full Text] [Related]
7. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis.
Griffiths CE; Strober BE; van de Kerkhof P; Ho V; Fidelus-Gort R; Yeilding N; Guzzo C; Xia Y; Zhou B; Li S; Dooley LT; Goldstein NH; Menter A;
N Engl J Med; 2010 Jan; 362(2):118-28. PubMed ID: 20071701
[TBL] [Abstract][Full Text] [Related]
8. Infections associated with the use of tumor necrosis factor-α inhibitors in psoriasis.
Tan X; Balkrishnan R; Feldman SR
J Drugs Dermatol; 2013 Mar; 12(3):e41-5. PubMed ID: 23545925
[TBL] [Abstract][Full Text] [Related]
9. Treatment of generalized vitiligo with anti-TNF-α Agents.
Alghamdi KM; Khurrum H; Taieb A; Ezzedine K
J Drugs Dermatol; 2012 Apr; 11(4):534-9. PubMed ID: 22453596
[TBL] [Abstract][Full Text] [Related]
10. The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study.
Julià M; Guilabert A; Lozano F; Suarez-Casasús B; Moreno N; Carrascosa JM; Ferrándiz C; Pedrosa E; Alsina-Gibert M; Mascaró JM
JAMA Dermatol; 2013 Sep; 149(9):1033-9. PubMed ID: 24048425
[TBL] [Abstract][Full Text] [Related]
11. Switching to adalimumab in patients with moderate to severe psoriasis who have failed on etanercept: a retrospective case cohort study.
Woolf RT; Smith CH; Robertson K; Barker JN
Br J Dermatol; 2010 Oct; 163(4):889-92. PubMed ID: 20854408
[No Abstract] [Full Text] [Related]
12. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
13. Detection of antibodies to anti-TNF agents in psoriatic patients: a preliminary study.
Cozzani E; Burlando M; Parodi A
G Ital Dermatol Venereol; 2013 Apr; 148(2):171-4. PubMed ID: 23588142
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study.
Esposito M; Giunta A; Mazzotta A; Zangrilli A; Babino G; Bavetta M; Perricone R; Chimenti S; Chimenti MS
Dermatology; 2012; 225(4):312-9. PubMed ID: 23295383
[TBL] [Abstract][Full Text] [Related]
15. The effect of tumor necrosis factor inhibitor therapy on the incidence of myocardial infarction in patients with psoriasis: a retrospective study.
Shaaban D; Al-Mutairi N
J Dermatolog Treat; 2018 Feb; 29(1):3-7. PubMed ID: 27881030
[TBL] [Abstract][Full Text] [Related]
16. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
17. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
[TBL] [Abstract][Full Text] [Related]
18. Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.
Gniadecki R; Kragballe K; Dam TN; Skov L
Br J Dermatol; 2011 May; 164(5):1091-6. PubMed ID: 21219290
[TBL] [Abstract][Full Text] [Related]
19. Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis.
van den Reek JM; van Lümig PP; Driessen RJ; van de Kerkhof PC; Seyger MM; Kievit W; de Jong EM
Br J Dermatol; 2014 Feb; 170(2):415-24. PubMed ID: 24117023
[TBL] [Abstract][Full Text] [Related]
20. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus.
Martínez-Abundis E; Reynoso-von Drateln C; Hernández-Salazar E; González-Ortiz M
Arch Dermatol Res; 2007 Nov; 299(9):461-5. PubMed ID: 17726611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]